Paul Nolte Quotes (33 Quotes)

Overall it doesn't look too bad. The prices paid is a concern. We'd like to see it come down a little. It's an inflationary key.

But whether the market is going to have the staying power beyond today, I think we will be able to determine that toward the close,

So what is an investor to do Based on Friday's response, it may yet be a long dark winter.

Stocks have had a real tough time maintaining gains this whole week. When we start taking a look around, gains tend to evaporate. Today, investors are looking at tech leaders. Those stocks are where the weight is being carried.

But that's more of a short-term phenomenon than anything worth paying a lot of attention to, ... it's going to come down to better economic numbers.

The foreign markets are on an absolute tear, so there's some thought that the liquidity might start coming back into the U.S. markets.

After a nice rally, investors are just taking a little bit of money off the table.

We went from being expensive 10 years ago to crazy expensive, and now we're back to just expensive.

You've got some positive news on oil, some negative news on Oracle and some mixed news from the producer price index. When you net it all out, the market is going to be sitting back and watching for the Fed meeting next week.

Hickel Karl Marx's key error is the idea that capitalism develops according to laws, that these laws are described by the tendency of the profit rate to drop, and that in the long run the system must collapse. This hypothesis has proven to be wrong, because capitalism has repeatedly found new ways of dealing with its crises. Through this inevitability of capitalism, Marx underestimates the need for political shaping. ... Marx fundamentally underestimated the nature of liberal democracy, he didn't comprehend liberal democracy. Concepts such as tolerance, civil rights and liberties, parlamentarianism - all these categories went totally unrecognised by Marx, and that had fatal consequences.

Already the futures markets are pricing in another rate hike and talk about a 5.0-plus fed funds rate is making the rounds. The currently inverted yield curve may also be a signal to the Fed that the economic growth of the past couple of years may be waning and any added tightening may be like kicking a good man while he is down.

We ran out of gas after yesterday's large advance. We only had earnings news from a couple companies today, and that couldn't carry us.

Right now sentiment is all loaded on one side of the market. It gives you the idea we're running late in the game -- we may be in the process of putting in a short-term top in the market.

Few companies are pounding the table and saying things are terrific so there's not the wild enthusiasm you would expect with a good earnings season,

The numbers are good from the Fed's perspective, even with November's ramped up numbers. Job growth is still slow and wage pressure has been nonexistent all year. If trends continue it could put pressure on the consumer. We may see the Fed have one more rate hike and then (be) done.

We have strong volume on down days, and weak volume on up days. That's the trend for the last couple weeks. That's telling that investors are more interested in selling than they are buying.

We're still absorbing a lot of things. The risks right now are certainly still with the bond market. It's providing some good competition for stocks.

I don't see inflation as a big deal in the classic sense. There are no wage pressures and no cost overruns. We're seeing inflation mainly in the price of gas and other commodities,

We have some continuation of the good news from yesterday.

I know people are focusing in on the dollar, but if we take a look at last week's strong action, our view at least, is that the underlying economy does not warrant it.

Now, instead of every bit of good news being hailed as the latest sign of recovery, it is being scorned as another nail in the coffin for easy money.

There is some concern over drugs coming off of patents and the expense of those drugs, and in some cases, such as with Pfizer and Merck, the efficacy issues, ... But we still can't get away from the fact that we're looking at an aging population and drugs are an integral part of keeping us going as long as we possibly can.

The important decisions haven't been made yet. You get the impression that there's not much really moving and ask yourself whether the optimism is really justified.

What a difference a week makes, from improprieties in the Japanese markets to still-higher oil prices amid diplomatic rumblings in the Middle East to less than stellar earnings.

To a certain extent, Bush's speech about increased spending in the U.S. Gulf Coast is helping the market. I am not too terribly surprised that consumer confidence is low because the number is colored by Katrina.

If you look at how the markets have been trading the last few days, we're seeing a much broader decline. We're not seeing a leader that can carry the day. It's not limited to a few stocks anymore. Disappointment is broadening out during this earnings cycl

On a year-over-year basis, the inflation figures are not anything to be concerned about.

The economic numbers are driving the bus. As long as the numbers remain kind of weak, if it doesn't look like we're getting much of a turnaround, then markets can continue to slide.

I don't expect to see a sharp movement in stocks -- it will be a gradual erosion over time.

We're getting a moderation in bond yields, and energy prices came down today. We're looking at things more favorably than this morning. There's still residual analysis about the Federal Reserve, and we're seeing some gamesmanship heading into next week's meeting, debating how more hikes we have.

Those that are left to trade seem to be going through the motions until year-end. The economic news today was expected based on last week's CPI number, so it was no surprise and couldn't sustain us until the end of the session.

We still like the fact that we're in an environment where no matter what happens in the economy, they (pharmaceutical companies) are still going to be doing business.

We're struggling with higher energy prices and also the rise in bonds, which is providing some competition for stocks.